skip to content

Market News

Vectura to present VR942 positive Phase I data

22 May 2017 07:18

Vectura Group and co-development partner UCB will present the positive outcomes of the Phase I clinical study (VR942-1-001) for their innovative inhaled biologic VR942 (UCB4144) today.

This followed the group's announcement in June 2016 that the study met its primary objective of evaluating the safety and tolerability of once daily VR942 single or repeat doses, administered as a dry powder via inhalation, in healthy volunteers and mild asthmatics respectively.

This industry-leading collaborative development programme represents the first example of an inhaled anti-IL-13 monoclonal fragment antibody successfully completing a Phase I clinical study with safety, tolerability and pharmacodynamic data supporting the relevance of drug delivery direct to the lung and the site of IL-13 expression.

This programme represents an exciting opportunity with biologics. Currently there are over 6 million patients with severe persistent asthma in major markets, of which 20% are uncontrolled.

The outcomes of the Phase I clinical study were being presented at the American Thoracic Society 2017 International Conference in Washington.

Story provided by

Related Company: VEC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.